Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Infect. 2017 Oct 20;76(1):44–54. doi: 10.1016/j.jinf.2017.10.007

Figure 2.

Figure 2

a-c: Number of total TB drugs (a), potentially active* (b), and known active** (c) TB drugs at each time point for 105 MDR-TB patients under follow-up.

*Potentially active: Assuming susceptibility where DST for a specific drug was missing.

**Known active: Only including known DST results and not assuming susceptibility for missing DST.